Non-motor Symptoms and Brain Dopamine Transporter Binding
Active, not recruiting
- Conditions
- ParkinsonismParkinson Disease
- Registration Number
- NCT02650843
- Lead Sponsor
- Turku University Hospital
- Brief Summary
This project aims to clarify the role non-motor symptoms in the development of Parkinson's disease (PD) and to improve diagnostics at very early stages of PD. The project involves multidimensional measures of disease biomarkers together with brain dopamine transporter (DAT) imaging with \[123I\]FP-CIT single photon emission computed tomography (SPECT).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 455
Inclusion Criteria
- Male or Female
- Age 18-100 years
- Referred for clinical DAT SPECT in Turku or Helsinki
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DAT SPECT striatal specific binding ratio Up to 10 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link non-motor symptoms to dopamine transporter binding in Parkinson's disease?
How does DAT SPECT imaging improve early PD diagnosis compared to standard clinical assessments?
Which non-motor symptom biomarkers correlate with DAT binding in prodromal Parkinsonism?
What adverse events are associated with DAT imaging using [123I]FP-CIT in PD research?
How do DAT binding patterns in NCT02650843 compare to LRRK2 or GBA mutation-related PD subtypes?